Search

Objective: To observe the effect of Danhong injection (DHI) on perioperative metabolomics of unstable angina pectoris (UA) with blood stasis syndrome. Materials and Methods: A prospective, randomized, controlled, and single-blind clinical trial was conducted. Sixty-one UA patients with traditional Chinese medicine blood stasis syndrome undergoing elective percutaneous coronary intervention (PCI) were randomly divided into the Danhong and control groups, and 10 healthy volunteers were included as baseline. The Danhong group received western medicine + DHI treatment, while the control group received western medicine + saline. Nontargeted metabolomics was used to analyze the serum metabolites of healthy volunteers in the Danhong and control groups before and 5 days after PCI. Results: Before treatment, there was no significant difference in serum metabolites between the Danhong and control groups, but there was a significant difference between the two groups and the healthy group. Differential metabolites were clustered mainly in glycerophospholipid, sphingolipid, purine, and amino acid groups, which were generated in their metabolic pathways. After 5 days of PCI, the profiles of serum metabolites were significantly closer between the Danhong-or control-treated groups and that of the healthy group. Furthermore, DHI treatment converted the serum metabolite profile more to that of the healthy group than the control treatment. Conclusion: The beneficial effect of DHI on patients with unstable angina is reflected at the level of serum metabolic biomarkers.

Background: Peri-procedural myocardial injury (PMI) is a common complication of percutaneous coronary intervention (PCI), which cannot be entirely avoided using available treatments. The findings of earlier research have shown that Shen-Yuan-Dan (SYD) capsules, a traditional Chinese medicine, can potentially alleviating PMI. This study aimed to confirm further this hypothesis in a rigorous, well-designed randomized controlled study. Methods: Our clinical trial was randomized, double-blinded, and placebo-controlled. A total of 181 patients with unstable angina (UA) undergoing elective PCI were randomized to pretreatment with SYD or a placebo under the basis of conventional treatment; 87 patients were pretreated with SYD (4 capsules, 3 times a day, with a further 4 capsules 2 h before PCI) 3 days before the procedure, and 94 patients were given a placebo. No patients received reloading statins before PCI, and SYD or placebo was maintained for 1 month after PCI. The primary endpoint was the incidence of PMI. The secondary endpoint was calculating the incidence rate of all 30-day major adverse cardiovascular events (all-cause mortality, non-fatal myocardial infarction, unplanned revascularization). The safety outcomes, including abnormalities in electrocardiogram and serum biochemical examinations caused by drug use, were also tested. Results: The levels of creatine kinase-myocardial band (CK-MB) in both the SYD and placebo groups were increased at 4 h and 24 h after PCI compared with before the procedure (P